For what it's worth Bell Potter reiterated their buy recommendation but lowered their price target to $1.06 from $1.09.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025